Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease

Istanbul University49 enrolled

Overview

We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.

CONTEXT: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and extrarenal manifestations may be observed in many organ systems. Hypothalamus-pituitary-adrenal axis in patients with ADPKD was not evaluated extensively. OBJECTIVE: We aimed to evaluate the hypothalamus-pituitary-adrenal axis in ADPKD patients. METHODS: Twenty two ADPKD patients and 27 healthy subjects were enrolled. Basal dehydroepiandrosterone-sulfate (DHEAS) levels and cortisol and dehydroepiandrosterone responses to low dose short adrenocorticotropin stimulation test were assessed. Correlation analyses of these parameters with glomerular filtration rates, renal volumes and pain characteristics in patients with ADPKD were done.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

TetracosactinDRUG

1 microgram tetracosactin, intravenous injection, once for the test

Eligibility

Sex: ALLMin age: 20 YearsMax age: 56 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy subjects * Diagnosis of autosomal dominant polycystic kidney disease Exclusion Criteria: * A glomerular filtration rate below 60 ml/min * History of recent major surgery * Systemic infections with fever * Significant hirsutism (Ferriman Gallwey score≥8) * Congenital adrenal hyperplasia * Late onset congenital adrenal hyperplasia * Systemic corticosteroid use (including previous use) * Topical corticosteroid use * Menstrual irregularity * History of thromboembolism * Uncontrolled diabetes or hypertension * History of psychosis * Pregnancy * Lactation * History of hypersensitivity to tetracosactin

Locations (1)

Istanbul Univetsity, Istanbul Medical Faculty, Department of Internal Medicine

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Inadequate response to tetracosactin infusion

Time frame: 30 and 60 minutes after the drug is administered

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.